TOP TEN perturbations for Q96NG8 (Homo sapiens)

Organism: Homo sapiens
Gene: Q96NG8
Selected probe(set): 241602_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q96NG8 (241602_at) across 5880 perturbations tested by GENEVESTIGATOR:

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.7957325
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.7881069
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.5446262
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.4458427
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):1.3006516
Number of Samples:2 / 2
Experimental colchicine study 7 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

formaldehyde study 3 (4500ug/ml) / vehicle (EtOH) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):1.2273331
Number of Samples:3 / 3
Experimental formaldehyde study 3 (4500ug/ml)
Bronchial epithelial cells (NHBE) treated with 4500 ug/ml formaldehyde (within range of concentrations reported to induce toxicity in lung epithelial cells and other cell types) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker. ATC code:---
Control vehicle (EtOH) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (ethanol) at a final concentration of 2% v/v (concentration that ensures >80% cell viability after 24 hours of exposure) for 24 hours. NHBE cells were derived from a 60 year old male non-smoker.

exercise study 33 (OT; slow twitch; pre-exerc.) / exercise study 33 (YT; slow twitch; pre-exerc.)

Relative Expression (log2-ratio):1.2160034
Number of Samples:4 / 5
Experimental exercise study 33 (OT; slow twitch; pre-exerc.)
Slow twitch myosin heavy chain muscle fibers (MHC) I were obtained from vastus lateralis muscle. Biopsies were taken from old trained (OT) women (85±1 years) before the 36th (last) exercise session. Participants underwent 12 weeks of progressive resistance training including 36 training sessions (3 days/week) with three sets of 10 bilateral knee extensions at 70–75% of their one-repetition maximum (1 RM). Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.
Control exercise study 33 (YT; slow twitch; pre-exerc.)
Slow twitch myosin heavy chain muscle fibers (MHC) I were obtained from vastus lateralis muscle. Biopsies were taken from young trained (YT) women (23±2 years old) before the 36th (last) exercise session. Participants underwent 12 weeks of progressive resistance training including 36 training sessions (3 days/week) with three sets of 10 bilateral knee extensions at 70–75% of their one-repetition maximum (1 RM). Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-1.1381102
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)

Relative Expression (log2-ratio):1.0642204
Number of Samples:15 / 2
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):1.0346565
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.